IPO - ACTUATE THERAPEUTICS, INC.

Form Type: CORRESP

Filing Date: 2025-04-14

Corporate Action: Ipo

Type: New

Accession Number: 000168316825002547

Filing Summary: Actuate Therapeutics, Inc. submitted a request to the U.S. Securities and Exchange Commission to accelerate the effective date of its registration statement on Form S-1, File No. 333-286201, aiming for an effective date of April 16, 2025, at 5:00 p.m. Eastern Time. This request follows Rule 461 of the Securities Act of 1933, indicating that the Company is cognizant of its obligations under the Act. The Company requested notification of the effectiveness of the registration statement via telephone and in writing, specifically to its outside counsel, Baker & Hostetler LLP.

Form Type: S-1

Filing Date: 2025-03-28

Corporate Action: Ipo

Type: New

Accession Number: 000168316825001948

Filing Summary: Actuate Therapeutics, Inc. has filed a Form S-1 registration statement with the Securities and Exchange Commission as of March 28, 2025, to register the offer and sale of up to 3,904,374 shares of its common stock. The shares will be sold by B. Riley Principal Capital II, the selling stockholder, under a common stock purchase agreement dated March 27, 2025. Actuate Therapeutics is a clinical stage biopharmaceutical company focusing on developing therapies for challenging cancers through the inhibition of glycogen synthase kinase-3. Their lead drug, elraglusib, is currently in a Phase 2 trial for metastatic pancreatic ductal adenocarcinoma. They have not raised funds through this prospectus directly; however, they have the potential to receive up to $50 million from sales of common stock under the purchase agreement. The timing and quantity of shares sold will be at Actuate's discretion, subject to market conditions. The company is categorized as an emerging growth and smaller reporting company, allowing it to comply with reduced public company reporting requirements.